Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Crown Bioscience, Inc. and Horizon Discovery Announce Exclusive Two Year Agreement

Published: Wednesday, April 03, 2013
Last Updated: Wednesday, April 03, 2013
Bookmark and Share
Partnership to offer combined solutions for in vivo drug discovery model development.

Crown Bioscience, Inc. (Crown) and Horizon Discovery (Horizon) announced they have signed an exclusive two year collaboration agreement. Under the terms of the agreement Crown will be given access to Horizon’s proprietary collection of X-MAN isogenic cell lines to develop novel in vivo models for drug discovery.

The relationship is a continuation of a previous collaboration between the two companies. Horizon will share its X-MAN (X-Gene Mutant and Normal) cell lines with Crown to provide in vivo animal services to third parties. Crown will use Horizon’s cell lines to provide animal model development, study execution and business marketing to its clients. These high-quality disease models are crucial for generating ‘first-in-class’ patient-relevant targets while facilitating the development of novel oncology targets and early-stage drug discovery programs within the pharmaceutical industry.

By combining their drug discovery and translational research platforms, Crown Bioscience and Horizon Discovery will help their customers select and advance the highest quality drug candidates to clinical development. Both companies are ideally placed to help bring lead molecules based upon highly validated and novel drug models to clinic. In vitro and in vivo cell lines are available to clients who want to help validate new models and become early adopters, with complete access to new models available at the earliest possible phase.

“We are excited to continue working with Horizon through this new collaboration, and believe that the project will bring us closer to achieving a global leadership position in supporting oncology drug discovery programs. This exclusive agreement confirms Crown Bioscience’s position at the forefront of innovation within the global biotech and pharmaceutical industry,” said Jean-Pierre Wery, President of Crown Bioscience. “This is an important step on our path towards finding new answers to meet the urgent needs of our customers in their fight against cancer.”

“The suite of in vivo models developed with Crown will ideally complement our extensive range of in vitro drug discovery tools and services. We are confident this partnership will yield some exciting results,” commented Darrin Disley, CEO of Horizon Discovery. “This collaboration is further testament to the power and utility of Horizon’s gene editing technology in the creation of high value drug discovery tools.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Strengthens Immuno-Oncology Capabilities
Company has announced that it has developed and validated a unique set of models for immuno-oncology called HuGEMM™.
Friday, April 15, 2016
Crown Bioscience Expands Cardiovascular and Metabolic Disease Capabilities
Company has announced Zhen Pang as scientific director.
Thursday, October 15, 2015
Crown Bioscience Brings Top Scientists Together
Experts to discuss best approaches to advance translational oncology.
Saturday, October 03, 2015
Crown Bioscience Acquires Molecular Response’s PDX Business
Company is acquiring all of Molecular Response’s existing PDX models.
Friday, February 13, 2015
Crown Bioscience Expands Operations and Re-Brands UK Site
Existing facility will become centre of excellence for hormonal oncology and step up European operations.
Friday, January 09, 2015
Crown Bioscience Announces U.S. Expansion
New service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers.
Saturday, October 25, 2014
Crown Bioscience President Honored in PharmaVOICE 100
Dr Jean-Pierre Wery is recognized for pioneering work in translational medicine, improving the efficiency of drug discovery and development.
Friday, August 01, 2014
Crown Bioscience to Showcase Progression in Human Surrogate Trials
HuTrialTM demonstrates commitment to furthering preclinical understanding in order to improve personal care and increase patient recovery rates.
Wednesday, May 21, 2014
Crown Bioscience Receives $26.55M Series D Funding
Investment will fund rapid expansion in translational platform technologies for oncology and metabolic diseases.
Monday, May 12, 2014
Crown Bioscience Announces Research Collaboration with the NRCMM
New collaboration aims to develop disease-specific experimental models for translational medical research.
Saturday, May 10, 2014
Crown Bioscience Enters Strategic Partnership with SNBL
Agreement’s initial focus is for SNBL to promote Crown services to its Japanese client base.
Friday, April 25, 2014
Crown Bioscience Passes 1000 Model Mark in PDX Collection for Oncology Drug Discovery
Size of collection allows for more informed preclinical decision making on prospective drug candidates.
Wednesday, April 23, 2014
SIMM and Crown Bioscience Reach Landmark Agreement
Agreement to develop world-leading mouse clinical center and largest annotated PDX and translational oncology platform.
Friday, November 29, 2013
Crown Bioscience Enter Into a Business Collaboration with Xstrahl Ltd
Development of radiation models of cancer will enable the discovery of more effective oncology therapies.
Tuesday, October 15, 2013
Crown Bioscience Acquires PRECOS
Company strengthens oncology expertise.
Monday, August 05, 2013
Scientific News
NIH Launches Early-Stage Yellow Fever Vaccine Trial
Researchers at NIH have begun an early-stage clinical trial of an investigational vaccine designed to protect against yellow fever virus.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Viable HIV Vaccine Confirmed by Study
HIV Study in macaques confirms clinically viable vaccine opening the way for future treatment in humans.
PREVAIL Treatment Trial for Men with Persistent Ebola Viral RNA
The six-month study will enroll 60 to 120 EVD survivors.
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!